Grassi Investment Management Trimmed Enrgy Trnsfr Prt (ETP) Position By $977,400; Pieris Pharmaceuticals, Inc. (PIRS) Covered By 7 Bullish Analysts Last Week

Among 7 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals has $12.0 highest and $7 lowest target. $8.83’s average target is 0.80% above currents $8.76 stock price. Pieris Pharmaceuticals had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 13 by Roth Capital. As per Friday, November 10, the company rating was maintained by H.C. Wainwright. As per Friday, August 5, the company rating was reinitiated by Roth Capital. The company was initiated on Wednesday, July 22 by TH Capital. As per Tuesday, July 28, the company rating was initiated by Oppenheimer. The rating was maintained by H.C. Wainwright with “Buy” on Friday, August 11. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, May 30. On Wednesday, August 12 the stock rating was initiated by JMP Securities with “Market Outperform”. The firm has “Buy” rating by Roth Capital given on Wednesday, July 22. The company was maintained on Wednesday, March 9 by JMP Securities. See Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) latest ratings:

13/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
17/01/2018 Broker: William Blair Rating: Outperform Initiates Coverage On
20/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain

Grassi Investment Management decreased Enrgy Trnsfr Prt (ETP) stake by 30.89% reported in 2017Q3 SEC filing. Grassi Investment Management sold 54,300 shares as Enrgy Trnsfr Prt (ETP)’s stock declined 10.54%. The Grassi Investment Management holds 121,488 shares with $2.22M value, down from 175,788 last quarter. Enrgy Trnsfr Prt now has $21.93 billion valuation. The stock decreased 1.98% or $0.38 during the last trading session, reaching $18.84. About 5.11 million shares traded. Energy Transfer Partners, L.P. (NYSE:ETP) has declined 20.28% since February 28, 2017 and is downtrending. It has underperformed by 36.98% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $439.79 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

The stock decreased 1.13% or $0.1 during the last trading session, reaching $8.76. About 723,254 shares traded. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 128.81% since February 28, 2017 and is uptrending. It has outperformed by 112.11% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter:


Recent Posts